All News
FDA Grants Priority Review and EMA Accepts Regulatory Submission for Pfizer’s Abrocitinib, an Oral Once-Daily JAK1 Inhibitor, for Patients 12 and Up with Moderate to Severe Atopic Dermatitis https://t.co/I2dzetdgBw
Links:
Dr. John Cush RheumNow ( View Tweet)
RheumNow Podcast is UP! ACR 20 is Coming to Town - news on melanoma, COVID biologics & autoantibodies, Hepatitis & JAKs, Safety of nintedinib, upcoming ACR2020. Watch it here> https://t.co/np5aFCo9FB or listen on Apple> https://t.co/FHJv01AAbC or Android> https://t.co/qxuBmiNxU0
Links:
Dr. John Cush RheumNow ( View Tweet)
RheumNow Podcast is UP! ACR 20 is Coming to Town - news on melanoma, COVID biologics & autoantibodies, Hepatitis & JAKs, Safety of nintedinib, upcoming ACR2020. Watch it here> https://t.co/np5aFCo9FB or listen on Apple> https://t.co/FHJv01AAbC or Android> https://t.co/qxuBmiNxU0
Links:
Dr. John Cush RheumNow ( View Tweet)
RheumNow Podcast is UP! ACR 20 is Coming to Town - news on melanoma, COVID biologics & autoantibodies, Hepatitis & JAKs, Safety of nintedinib, upcoming ACR2020. Watch it here> https://t.co/np5aFCo9FB or listen on Apple> https://t.co/FHJv01AAbC or Android> https://t.co/qxuBmiNxU0
Links:
Dr. John Cush RheumNow ( View Tweet)
RheumNow Podcast – ACR 20 is Coming to Town (10.30.20)
Dr Jack Cush overviews the RheumNow commitment, upcoming bonus coverage of ACR20 and the good news and journal reports from the past week on RheumNow.com
Read Article
25 pts w/ refractory Juvenile dermatomyositis (JDM) were treated w/ JAK inhib (tofacitinib, ruxolitinib) - all showed improved rashes, including 66.7% with complete resolution; 40% had decreased muscle strength; 28% discontinued glucocorticoids https://t.co/wln0FrI0Iz
Links:
Dr. John Cush RheumNow ( View Tweet)
PI facts: did you know that JAK inhibitors(UPA, Bari, Tofa) have a warning against use w/ severe liver problems. They have not been studied in pts w/ Hepatitis B or C. UPA Bari & toga can be used in mild liver dz; Tofa only at 5 mg/d w/ moderate liver dz https://t.co/lnXrf12tjA
Links:
Dr. John Cush RheumNow ( View Tweet)
Latest data Global Rheumatology Alliance COVID Registry -2121 pts (40% RA, 17% SLE, 9% PsA), 64% on DMARDs, 33% biologics, 5% JAKi, 34% steroid,27% HCQ, with only 7.6 deaths and 39% hospitalized and 81% resolved infection. https://t.co/g0w4QZHmRl
Links:
Dr. John Cush RheumNow ( View Tweet)